TY - JOUR
T1 - MUTYH-associated polyposis
T2 - Review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa): MUTYH-associated polyposis: review and French recommendations
AU - Colas, Chrystelle
AU - Bonadona, Valérie
AU - Baert-Desurmont, Stéphanie
AU - Bonnet, Delphine
AU - Coulet, Florence
AU - Dhooge, Marion
AU - Saurin, Jean Christophe
AU - Remenieras, Audrey
AU - Bignon, Yves Jean
AU - Caron, Olivier
AU - De Pauw, Antoine
AU - Buisine, Marie Pierre
AU - Buecher, Bruno
N1 - Publisher Copyright:
© 2020 Elsevier Masson SAS
PY - 2020/12/1
Y1 - 2020/12/1
N2 - MUTYH-associated polyposis (MAP) was first described in 2002. It is an autosomal recessive condition associated with germline pathogenic variants of both MUTYH alleles. In 2011, a group of French experts reviewed the available data on this syndrome and established recommendations concerning the indications and strategies for molecular analysis of the MUTYH gene in index cases and their relatives, as well as the clinical management of affected individuals under the auspices of the French Institut National du Cancer (INCa). Some of these recommendations have become obsolete as a result of recent progress, especially those concerning the molecular strategy for MUTYH testing, as this gene has recently been included in a consensus panel of 14 colorectal cancer predisposition genes, justifying revision of the previous report. We report here the revised version of this work, which successively considers the phenotype and tumor risks associated with this genotype, differential diagnoses, criteria and strategy for molecular genetic testing and recommendations for the management of affected individuals. We also discuss the phenotype and tumor risks associated with monoallelic pathogenic variants of MUTYH.
AB - MUTYH-associated polyposis (MAP) was first described in 2002. It is an autosomal recessive condition associated with germline pathogenic variants of both MUTYH alleles. In 2011, a group of French experts reviewed the available data on this syndrome and established recommendations concerning the indications and strategies for molecular analysis of the MUTYH gene in index cases and their relatives, as well as the clinical management of affected individuals under the auspices of the French Institut National du Cancer (INCa). Some of these recommendations have become obsolete as a result of recent progress, especially those concerning the molecular strategy for MUTYH testing, as this gene has recently been included in a consensus panel of 14 colorectal cancer predisposition genes, justifying revision of the previous report. We report here the revised version of this work, which successively considers the phenotype and tumor risks associated with this genotype, differential diagnoses, criteria and strategy for molecular genetic testing and recommendations for the management of affected individuals. We also discuss the phenotype and tumor risks associated with monoallelic pathogenic variants of MUTYH.
KW - Colorectal adenomatous polyposis
KW - Hereditary colorectal cancer
KW - MUTYH
KW - Multigene panel
UR - http://www.scopus.com/inward/record.url?scp=85093919567&partnerID=8YFLogxK
U2 - 10.1016/j.ejmg.2020.104078
DO - 10.1016/j.ejmg.2020.104078
M3 - Review article
C2 - 33059073
AN - SCOPUS:85093919567
SN - 1769-7212
VL - 63
JO - European Journal of Medical Genetics
JF - European Journal of Medical Genetics
IS - 12
M1 - 104078
ER -